A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
Items 501–600 of 720
Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease
O’Keeffe, J., Kingshill, C., Tompson, J., South, A. M., & Baker-Smith, C. M. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01375-6 · Cited by 1
“These agents include: topiramate/phentermine [59 ], orlistat [ 60 ], and the glucagon-like-peptide-1 receptor agonists (GLP-1RA)s, liraglutide [ 61 ] and semaglutide [ 62 , 63 ].”
Bouhmouch, S., Dubern, B., Terraz, C., & Tounian, P. (2026) · Archives de Pédiatrie · doi:10.1016/j.arcped.2026.105545 · Cited by 1
Targeting the GLP-1 receptor pathways for dual management of obesity and depression
Keswani, R., & Bhatt, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104727 · Cited by 2
Christison, A. L., Kim, R., King, E. C., Sahay, R. D., Kharofa, R. Y., Sweeney, B. R., Thaker, V., Tucker, J. M., Vidmar, A. P., Yee, J. K., et al. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70127 · Cited by 1
Alanizi, A. H., Alruwythi, G. M., Alotaibi, N. H., Alanazi, N. H., Alghurabi, A. M., Qubaiban, R., & Alsubaie, N. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1959617 · Cited by 1
Nur mit Kalorien zu jonglieren, greift bei Adipositas oft zu kurz
Blüher, M. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3752-7 · Cited by 1
“Maßgeblich für die Zulassungsentscheidung war eine 2020 publizierte Studie [15].”
BackgroundObesity as a Neurobiologic Disorder: A Heavyweight Contender
Chávez-Castillo, M., Durán, P., Garrido, B., Díaz, A., Escalona, D., & Cano, C. (2022) · Current Psychiatry Research and Reviews · doi:10.2174/2666082218666220527120848 · Cited by 2
Liraglutida como manejo de pacientes con pérdida de peso inadecuada posterior a manga gástrica
Castaño, D. K. S., Abreu-Lomba, A., Florez, S. Q., & Corredor, L. M. A. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.3.689 · Cited by 1
“[11] Kelly AS, Auerbach P, Barrientos-Pérez M, Gies I, Hale PM, Marcus C, et al.”
BackgroundRichter, L. R., Albert, B. I., Zhang, L., Ostropolets, A., Zitsman, J. L., Fennoy, I., Albers, D. J., & Hripcsak, G. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.923704 · Cited by 4
“Supporting this is the general success of novel classes of anti-diabetic drugs leveraging GLP-1 receptor agonists to manage T2DM and obesity in adults and adolescents (Kelly et al., 2020).”
BackgroundObésité infantile : nouveautés thérapeutiques ciblées
Arana, I. L. R., Bouthors, T., Borloz, S., Hauschild, M., Maggio, A. B. R., & Schwitzgebel, V. (2023) · JMIG · doi:10.53738/revmed.2023.19.815.374 · Cited by 1
The Swedish Youth with Obesity cohort: Profile of an ongoing prospective study
Christenson, A., Bonn, S. E., Torgerson, J., Hjort, S., Dreber, H., & Lagerros, Y. T. (2023) · Obesity · doi:10.1002/oby.23747 · Cited by 1
“Additional treatment components are available after individual medical evaluation by a physician, such as weight loss drugs [13], for”
BackgroundPharmacotherapeutic options for the management of obesity in children
Aldhafiri, A. J. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.225432.1194 · Cited by 1
Type 2 Diabetes and Pre-Diabetes in Pediatric Obesity
Bensignor, M. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_9 · Cited by 1
Veretekhina, T. V., St. Petersburg, R. F., & Yarmolinskaya, M. I. (2024) · Women s Health and Reproduction · doi:10.31550/2712-8598-2024-1-1-zhzir · Cited by 1
Pharmakotherapie der Adipositas
Roser, P. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01167-z · Cited by 1
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Holder, M., Kapellen, T., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R., Holterhus, P., Karges, B., Kordonouri, O., et al. (2024) · Experimental and clinical endocrinology & diabetes · doi:10.1055/a-2166-6730 · Cited by 2
Empowering Families and Providers With a Lifestyle Medicine Approach to Pediatric Obesity
Amati, J. B., & Brackbill, E. L. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241238682 · Cited by 2
“22,23 22-25 Additionally, recent reports of suicidal thoughts linked to the use of GLP-1s are drawing increased scrutiny from both European regulators and the FDA.”
Wang, M., Li, H., Liu, C., Zhang, Y., Wu, Q., & Yang, Y. (2024) · Current Drug Metabolism · doi:10.2174/0113892002289388240705113755 · Cited by 2
Hales, C. M., Ogden, C. L., Freedman, D. S., Sahu, K., Hale, P. M., Mamadi, R., & Kelly, A. S. (2024) · Childhood Obesity · doi:10.1089/chi.2024.0248 · Cited by 1
Self-citationSecond Generation Anti-Obesity Medications
Chimatapu, S. N., Mittelman, S. D., & Singhal, V. (2024) · Current Pediatrics Reports · doi:10.1007/s40124-024-00326-6 · Cited by 2
“Liraglutide’s efficacy in pediatric obesity was primarily assessed in a randomized, double-blind, placebo-controlled trial [20].”
InfluentialLundqvist, T., Stenlid, R., & Halldin, M. (2025) · Metabolites · doi:10.3390/metabo15040235 · Cited by 4
Chinn, J. O., Baidal, J. W., Pratt, J. S. A., Shepard, W. E., & Fell, G. L. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114610 · Cited by 2
Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting
Barajas, A. G., Gagnon, C. A., & Schmitt, J. A. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70053 · Cited by 1
“…agonists in the management of paediatric T2D becomes more routine and standard of care [14], we aimed to add to the existing literature [3, 15, 16] by analysing the effects of GLP-1 receptor agonists on metabolic health and insulin needs in real-world settings for a paediatric cohort with T2D…”
Ponzoni, M., Rea, F., Corrao, G., Barron, D. J., Cantarutti, A., & Morabito, G. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.05.020 · Cited by 1
Obesidad y diabetes mellitus tipo 2: tratamiento farmacológico
Martos‐Moreno, G. Á., & Oliver, J. A. (2025) · Pediatría Integral · doi:10.63149/j.pedint.47 · Cited by 1
New directions in childhood obesity treatment – A path forward or wishful thinking?
Reilly, J. L., Arora, S., Chatman, K., Cooper, Z., & Hsia, D. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.010 · Cited by 1
Hornack, S. E., Vaidya, S. S., Chevinsky, J. D., O’Connor, R. J., & Latif, F. (2025) · Psychiatric Annals · doi:10.3928/00485713-20250915-02 · Cited by 1
Fifteen-minute consultation: The child with obesity
Low, A., Parry-Okeden, S., Ferguson, E. C., Wright, N. P., & Elder, C. J. (2021) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2020-321029 · Cited by 1
Key articles and guidelines for the pediatric clinical pharmacist from 2019 and 2020
Bobo, K. S., Cober, M. P., Eiland, L. S., Heigham, M. K., King, M., Johnson, P. N., Miller, J. L., & Sierra, C. M. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab426 · Cited by 1
Modern Approaches to the Management of Obesity in Children: Novelties
Girsh, Y. V., Surgut, R. F., & Verkhovykh, E. V. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-10-61-67 · Cited by 1
“В таких случаях для повышения эффективности используется фармакотерапия, которая облегчает выполнение рекомендаций по питанию, помогает в формировании новых навыков рационального питания и ПП, способствует длительному поддержанию достигнутого эффекта в уменьшении массы тела [6, 13, 14].”
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1515-8694 · Cited by 1
Food Allergen Elimination for Adolescent Pre-diabetes Reduction
(2022) · British Journal of Gastroenterology · doi:10.31488/bjg.1000131 · Cited by 1
The Use of Evidence-Based Dietary Interventions for the Management of Obesity
Busetto, L., Casanueva, F. F., Ard, J. D., der Schueren, B. V., & Burguera, B. G. (2023) · European Medical Journal · doi:10.33590/emj/10302068 · Cited by 1
Kramer, R. E. (2023) · Current Gastroenterology Reports · doi:10.1007/s11894-023-00894-5 · Cited by 2
“Though the advent of new Glucagon-like peptide-1 receptor agonists (GLP1RA) such as liraglutide [5] and semaglutide [6] have shown promising results in adults, there are limited studies in adolescents [7, 8].”
BackgroundPrevention and Treatment of Obesity in Children
Hitt, T. A., Wasserstein, K. L., Malina, S. N., & Magge, S. N. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_51 · Cited by 1
The Treatment of Childhood and Adolescent Obesity
Armstrong, S., & Farpour‐Lambert, N. J. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch27 · Cited by 1
Cerroni, C., Steiner, A., Seanez, L., Kwon, S.-H., & Lewis, A. S. (2023) · bioRxiv · doi:10.1101/2023.04.21.537724
“Clinical trials have also shown benefit for the GLP-1R agonists liraglutide [5], semaglutide [6], and exenatide [7] in treating pediatric obesity.”
BackgroundMessiah, S. E., Ernest, D. K., Cruz-Munoz, N. F. D. L., Lipshultz, S. E., & Barlow, S. E. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114616 · Cited by 1
Vashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.08.13.25333579 · Cited by 2
Obesity: A Concise Review and Key Points
Malek, E. (2020) · Global Journal of Pediatrics & Neonatal Care · doi:10.33552/gjpnc.2020.02.000544
“showed promising results in the 12-18 year-old obese patients [7].”
BackgroundGLP-1-Analoga in der Therapie des Typ-2-Diabetes bei Jugendlichen
Veyder-Malberg, C., Furthner, D., Dalus, C., Maruszczak, K., Schneider, A.-M., & Weghuber, D. (2020) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-020-01073-w
Youth Along the T2D Risk Continuum Remain Concerningly Refractory to Therapeutic Interventions
Wolfgram, P. M., & Cabrera, S. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab292
Management of severe pediatric obesity
Chung, L. Y., & Rhie, Y. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.6.416
“Liraglutide [50] GLP-1 agonist Liraglutide 3.”
Nundy, S., Kakar, A., & Bhutta, Z. A. (2021) · Springer eBooks · doi:10.1007/978-981-16-5248-6_16 · Cited by 1
思想的飞刀:是百无一用还是百发百中——读《影响世界历史的100名著排行榜》
孔庆典 (2006) · 民主与科学
A Case Report of Severe Osteomalacia in a Young Patient After Bariatric Surgery
Alarfaj, H. M., Alrasheed, W. Y., Alsulaiman, S. A., Almulhem, F. T., Almaideni, M. F., & AlKuwaity, K. W. (2021) · Cureus · doi:10.7759/cureus.20198 · Cited by 1
“Moreover, liraglutide, which is a glucagon-like peptide 1 (GLP-1) analog, has been approved by the FDA and European Medicines Agency as a medical treatment that promotes weight loss [14].”
BackgroundPrecision medicine in childhood obesities
Martos‐Moreno, G. Á., & Argente, J. (2021) · ANALES RANM · doi:10.32440/ar.2021.138.03.rev03 · Cited by 3
Adipositas bei Kindern und Jugendlichen
Weihe, P., & Blüher, S. (2022) · Allgemein- und Viszeralchirurgie up2date · doi:10.1055/a-1671-1917
Profitieren adipöse Jugendliche von Liraglutid?
(2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1265-1721
Profitieren adipöse Jugendliche von Liraglutid?
(2020) · Pädiatrie up2date · doi:10.1055/a-1211-0207
Liraglutide for Weight Reduction in Obese Adolescents
(2020) · AAP Grand Rounds · doi:10.1542/gr.44-2-19
Patel, C., Warhadpande, M., & Jacobson, M. Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818872-9.00033-9
Impact of obesity on esophageal physiology in pediatrics
Patton, T. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98365-5.00011-5 · Cited by 1
Insulin Resistance and Other Mechanisms of Obesity Hypertension
Thaker, V., & Falkner, B. E. (2022) · Springer eBooks · doi:10.1007/978-3-319-31420-4_39-2
The pharmacological treatment of obesity: A historical perspective
Cuenca-Ecuador., U. C. D. C., Pacheco, A. V. G., Peláez, C. E. A., & Ortíz, R. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.s3.27
Are GLP-1 agonists effective for weight loss in obese nondiabetic pediatric patients?
Tout, W., & Nagarajan, P. (2022) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001644
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1849-0342
Efeitos colaterais da liraglutida em pessoas não diabéticas: uma revisão integrativa da literatura
de Oliveira, A. F. M., Silva, G. C., & Barros, N. B. D. (2022) · Brazilian Journal of Development · doi:10.34117/bjdv8n12-028
Kim, M. C., & Yum, K. (2022) · Korean Journal of Family Practice · doi:10.21215/kjfp.2022.12.5.361
Ungdom med alvorlig fedme bør få legemiddel på blå resept
Ødegård, R. A., Júlíusson, P. B., Kokkvoll, A. S., Kristiansen, H., Köpp, U. M. S., Rolin, J., Shah, S., Svendsen, M., & Hjelmesaeth, J. S. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0069
Major evidence of the GLP-1 analog (liraglutide) in the treatment of obesity: a systematic review
Fernandes, F. B. (2023) · International Journal of Nutrology · doi:10.54448/ijn23211
Styne, D. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-09512-2_13
Modern methods of obesity treatment - review of the literature
Zygmunt-Siembida, E., Wróblewska, H., Zimna, A. I., Wróblewska, K., Kozdra, M., Piasek, L., & Osińska, A. (2023) · Quality in Sport · doi:10.12775/qs.2023.13.01.006
Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death
Srivastava, G. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100077
“Presently, orlistat, phentermine monotherapy, liraglutide [38], phentermine/topiramate have attained US FDA approval status in adolescents with semaglutide 2.4 mg soon following on December 23, 2022 given the remarkable re-sults of the STEP-TEENS trial [39].”
BackgroundInfluentialPrevention and Treatment of Obesity in Children
Hitt, T. A., Wasserstein, K. L., Malina, S. N., & Magge, S. N. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_51-1
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0009
Pharmacological Strategies for Pediatric Obesity
Fox, C. K., Raatz, S. J., & Sweeney, B. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_6 · Cited by 2
Case Study: Hashimoto’s Thyroiditis and Increased HbA1C
Nanda, P., & Singh, S. (2023) · International Journal of Diabetes Management · doi:10.61797/ijdm.v2i1.233
Semaglutide as Treatment for Obesity in Adolescents
Mikhail, N. E., & Wali, S. (2023) · International Journal of Diabetes Management · doi:10.61797/ijdm.v2i1.238
Debelost otrok in mladostnikov in težava stigmatizacije
Gantar, I. Š., & Vogrin, B. (2023) · doi:10.18690/um.mf.2.2023.8
ANOREXYGENOUS MEDICINES FOR CONTROLLING OBESITY IN CHILDHOOD AND ADOLESCENCE
Cristovão, T. C. B., Raiter, B. T., Galhardo, A. D. A., Chen, K. T., Rêgo, M. C. D., Psanquevich, A. K., Boaventura, B. F., de Ramos, K. B., & Galotti, R. (2024) · International Journal of Health Science · doi:10.22533/at.ed.159422330127
Management of the child with obesity: Role and development of new medications
Martos‐Moreno, G. Á., & Argente, J. (2024) · Global Pediatrics · doi:10.1016/j.gpeds.2023.100126
Metabolic syndrome in children and adolescent: South Asian perspective
Dabadghao, P., & Bhowmik, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00082-7 · Cited by 1
General Treatment of Pediatric Obesity
Benavent, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-26727-7_9
Severe obesity in youth: health implications and treatment strategies
van de Pas, K. G. H. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20240301kp
Últimas estrategias en el tratamiento de la obesidad: Una revisión sistemática
Acosta, J. A. H., Astudillo, L. D. P. B., Tú, E. E. C. S., Vélez, L. S. I., Zambrano, Y. R. Z., & Menéses, N. G. D. (2024) · Mediciencias UTA (Impresa)/Mediciencias UTA (En línea) · doi:10.31243/mdc.uta.v8i1.2305.2024
Characteristics of adolescents referred for bariatric surgery in Abu Dhabi, United Arab Emirates
Beck, R. H., Afrooz, I., Masalawala, M. S., Watad, R., Shaban, T. A., & Deeb, A. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1297251
“…medications prior to MBS, and, given the data supporting the ef fi cacy of glucagon-like peptide-1 receptor agonists in adolescents with obesity (55), further work is now required to de fi nitively establish the role for pharmacotherapy in bridging the gap between diet and lifestyle…”
MethodApproach to Childhood and Adolescent Obesity
(2024) · The Singapore Family Physician · doi:10.33591/sfp.49.9.u7
Medical treatment of pediatric obesity
Chung, L. Y. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.5.324
Semaglutide interferes with postnatal development of juvenile mice with compromised growthPreprint
Joly, A., Rebiffé, L., Dusabyinema, Y., Dellinger, J., Gauthier, K. C., Leulier, F., & Vadder, F. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592704
Prevention in Children, Adolescents, and Young Adults
Hayman, L. L., & Ryan, H. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_22
Genetic Obesity: The Current Treatment Options
(2024) · Journal of Obesity and Chronic Diseases · doi:10.17756/jocd.2024-051
Chernyadyev, А. D., Софронова, Л. В., Minaeva, N. V., & Михадовна, А. Р. (2024) · Perm Medical Journal · doi:10.17816/pmj41398-108
Pavlushynskyi, Y., & Makarchuk, O. M. (2024) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2024.1.14736
Childhood Weight Management in Practice
Stewart, L. (2024) · Child and Adolescent Obesity · doi:10.1002/9781119798873.ch11
Obesidad y riesgo cardiovascular: liraglutida y sus beneficios terapéuticos
Mendoza, W. M. M., Vaca, L. E. B., Bazurto, M. A. C., Velez, E. M. D. V., Pin, M. B. M., & Alencastro, J. A. P. (2024) · AlfaPublicaciones · doi:10.33262/ap.v6i3.1.526
“…medida el gasto energético, ya que incrementa el nivel de insulina postprandial de una manera dependiente de la glucosa, retrasa el vaciamiento gástrico, reduce la secreción de glucagón e induce la pérdida de peso a través de la reducción del apetito y la ingesta de energía (Kelly et al., 2020).”
BackgroundParums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.946675 · Cited by 2
“However, in the years since the end of the COVID-19 pandemic, persistent obesity in children and adolescents has resulted in clinical trials to evaluate the safety and efficacy of the GLP-1 mimics, semaglutide and liraglutide [22,23].”
BackgroundInfluentialUpdates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
Lega, S. (2024) · Medico e Bambino · doi:10.53126/meb43553
Endocrinologic Sequelae of Anorexia Nervosa and Obesity
Sisley, S. R., Gordon, C. M., & Sonabend, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_33
Medically Supervised Weight Loss and Effects of Anti-Obesity Medications
Sheer, A. J., Donahoo, W. T., & Johnson-Mann, C. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_14
Kim, Y. Y., Kim, J. H., & Shin, J. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00170 · Cited by 2
Management of Adolescent Obesity
Srivastava, G., Fatima, A., Madhar, A., & Paddu, N. U. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.002 · Cited by 2
Effectiveness and safety of liraglutide in the treatment of childhood obesity
Sharshova, O. G., Chubarov, T. V., Peterkova, V. A., Zhdanova, O. A., & Артющенко, А. И. (2024) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn18011
(2025) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610027700-ch30
The Use of Complementary and Alternative Treatments in Adolescent Obesity: A Narrative Review
Shrestha, M., Harris, A., Bailey, T., Savant, U., & Patel, D. R. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22020281 · Cited by 1
Cutaneous Manifestations of Obesity in the Pediatric Age Group: A Narrative Review
Rout, A. N., & Das, A. (2024) · Asian journal of pediatric dermatology. · doi:10.4103/ajpd.ajpd_19_24
Medikamentöse Therapie der Adipositas bei Kindern und Jugendlichen
Lischka, J., Torbahn, G., Mörwald, K., Gomahr, J., Jabbour, J., Geiersberger, S., & Weghuber, D. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02149-1 · Cited by 1
Evaluating and treating pediatric obesity: A practice update
Benton, R. (2025) · JAAPA · doi:10.1097/01.jaa.0000000000000194 · Cited by 1
“…is more effective when the family is included; In the study cited by the AAP advocating for GLP-1 RA use in adolescents, 43% of the patients taking liraglutide experienced a BMI reduction of at least 5%, and 26% of the patients experienced a BMI reduction of at least 10% 19 BMI by week 82.”
InfluentialObesity Management in Female Adolescents
Roth, L. P., Bernier, A. V., Gulley, L. D., Lohse, K., Whooten, R., Allen, L., Brink, H. V., Sfeir, J., Simon, S. L., Finn, E., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.15238 · Cited by 3
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.